Company number: 04620455 Registered Charity: 1099537
European Society for Clinical Virology (Limited by guarantee) Report and Financial Statements for the year ended 31 October 2024
11/08/2025 Page 1 of 10
European Society for Clinical Virology (Limited by Guarantee)
Members of Executive - Company Directors (November 1[st] 2023 - October 31[st] 2024)
Prof. Dr. Pamela Vallely (President) Prof Dr. Mariet C.W. Feltkamp (Past President) Prof. Dr. Annelies Riezebos-Brilman(Vice President) Prof. Dr. Maria São José Alexandre Nascimento (Vice President) Prof. Dr. Catherine Moore (General Secretary) Prof. Dr. Xavier López-Labrador (Communication Officer) Prof. Dr. George Sourvinos (Treasurer) Prof. Dr. Heli Harvala (Meetings Secretary)
Company Secretary
Ester Zoroa, Kenes Group, KAM
Page 2 of 10
European Society for Clinical Virology (Limited by Guarantee)
European Society for Clinical Virology (ESCV) details
Registered Office Charles Darwin House 12 Roger Street London Company limited by guarantee N° 04620455 Registered as a Charity in England N° 1099537
Inland Revenue reference: 610 94961 19846 A 01
Page 3 of 10
European Society for Clinical Virology (Limited by Guarantee)
Directors’ Report
The European Society for Clinical Virology (ESCV) is a Company Limited by Guarantee, first incorporated in 2003. In accordance with the Society’s Memorandum of Association, each Company Member undertakes to contribute such amount as may be required, not exceeding £1, to the Company’s assets if it should be wound up while he or she is a Company Member or within one year after he or she ceases to be so.
The Society is registered as a Charity, the Company Directors being the Charity’s Trustees.
The Company Directors acting collectively are the Society’s Executive.
The Executive hereby submits its report and financial statements for the year ending October 31[st] , 2024.
Organization and Objectives
According to the articles, the Society is administered by the Executive, made up of minimum three and maximum ten Company Directors/Charity Trustees. Currently the Executive numbers eight Directors.
The ESCV has appointed a professional secretariat to handle administrative matters. This secretariat is Kenes Group, Rue François-Versonnex 7, 1207 Geneva, Switzerland.
In accordance with Article 4 the Executive admits as ‘ESCV Members’ such persons and subjects them to such rights and obligations as it thinks fit. Such ‘ESCV Members’ are not Company Members for the purposes of the Articles and are not entitled to vote on any matter save where expressly provided in the Articles.
ESCV members of different European and other countries are represented by councilors, elected by each country’s members according to procedures described in the Articles. The councilors acting collectively are the Council. The Council elects the Company Directors/Charity Trustees according to procedures described in the Articles. The Society’s objectives are to promote public health and to advance public education, in particular medical education, by:
-
improving the knowledge of viruses, particularly as it relates to the diagnosis and management of viral diseases, their pathogenesis, natural history and prevention.
-
improving diagnostic methods.
-
promoting high standards in laboratory viral diagnosis through quality assessment activities and education; and
-
promoting or developing for the benefit of the public the preparation and exchange of reference reagents.
Reserves Policy
The Executive has the policy to maintain sufficient funds to allow the Society to meet its objectives and obligations on a long-term basis, and to provide a measure of investment income. It is the objective of the Society to utilize fully each year’s net income for its charitable activities.
Page 4 of 10
European Society for Clinical Virology (Limited by Guarantee)
Review of Activities in 2023/2024
Scientific Meetings
-
NGS workshop, 23[rd] and 24[th] January 2023. London (UK).
-
ESCV – ECCI workshop on Congenital CMV Infection, 26[th] and 27[th] April 2023. Crete (Greece).
-
25[th] Annual Conference of the ESCV, 30[th] August – 2[nd] of September 2023 Milan (Italy).
-
European Non-Polio Enterovirus Network (ENPEN) on Non-Polio Enteroviruses in Europe workshop, took place from 23-24 May 2024, in Corfu, Greece.
-
4th ESCV workshop on Next Generation Sequencing in Clinical Virology, took place from the 10 – 11 June 2024 in Stockholm, Sweden.
-
26[th] Annual Conference of the ESCV, 17-21[st] of September 2024 Frankfurt, Germany.
Awards given at the 26[th ] Annual Conference of the European Society for Clinical Virology 2024 (Frankfurt)
-
European Diagnostic Virology (former Abbott Award) 2024 to Dr. Julianne Brown.
-
BioMerieux Award 2024 to Prof. Mariet Feltkamp.
-
Gardner Lectureship Award 2024 to Dr. Hans Hellmuth Hirsch.
-
Heine-Medin Award 2024 to Dr. Emma Hodcrof
Travel grants and fellowships given
- 22 virologists received a grant to attend the 26[th] Annual Conference of the European Society for Clinical Virology
Training grants
- None
Business Meetings held
-
ESCV Executive Meetings were held on 24[th] of January, 22[nd] of February, 25[th] of March, 22[nd] of April, 24[th] of May, 27[th] of June, 25[th] of July, 18[th] of September, 24[th] of October, 28[th] of November and 16[th] of December 2024.
-
Council Meeting was held on 19[th] of September 2024.
-
General Assembly was held on 20[th] of September 2024.
Page 5 of 10
European Society for Clinical Virology (Limited by Guarantee)
Future Scientific Meetings planned
- 27[th] Annual Conference of the ESCV, 17[th] – 20[th] of September 2025 (Thessaloniki, Greece).
Signed on behalf of the Executive (Company Directors),
Prof. Dr. Pam Vallely Company President
Page 6 of 10
European Society for Clinical Virology (Limited by Guarantee)
Statement of financial activities (incorporating the income and expenditure account) Year ended 31 0ctober 2024
Page 7 of 10
European Society for Clinical Virology (Limited by Guarantee) EITRIIPL4N %()LIETY F()R LLINICAL VIRI)L(M'Y. LI)DI)I¥l & ExpeJLges fnmi l.YoYember21b23 to JI I)ctur 24124 2024 ELIt 2024 GBP 11.X34.a) 2023 EUR 20 Not& U.¥57Y(I Merthrship feos Spo]Lsorship C(gre5 Income 24.490 10.500 37'6f0) 20.432 30.583 5.6111 47,718 26.679 4.1 41'62X 31,427 611.619 83,919 73.2111 Trnvel gTants 51.540 43'W5 X'7N) 74.536 84.57 73.783 WurLthop exF]e5 Congre%5 £xneS Pmjecl JollfDai expett5e5 Admini%tratii'e expenses Bank chaTg& Estr¥d5[wY ¢A]*J 89.340 91.469 23.3711 79.795 20.394 24'>12 .755 27.640 3.814 20,309 4'69(1 17'(AO 4.091 15.389 5.761 23.ofd 3.1x2 213.937 I78.? 228,359 IYJ'213 ofthe yr -14l'278 .1 l7'868 -144. -I26'005 Page8of10
European Society for Clinical Virology (Limited by Guarantee)
Audit Exemption
(a) For the year ended 31 October 2024 the company was entitled to exemption from audit under section 477(2) of the Companies Act 2006 relating to small companies.
(b) Members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476 of the Companies Act 2006.
- (c) The directors acknowledge their responsibility for:
i. ensuring the company keeps accounting records which comply with section 386; and
ii. preparing accounts which give a true and fair view of the state of affairs of the company as at the end of the financial year, and of its profit or loss for the financial year, in accordance with the requirements of section 393, and which otherwise comply with the requirements of the Companies Act relating to accounts, so far as applicable to the company.
(d) These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies’ regime.
Approved by Executive on 16[th] of July 2025 and signed on its behalf by Prof. Dr. Pam Vallely (Company President).
Prof. Pamela Vallely Company President
Page 9 of 10
European Society for Clinical Virology (Limited by Guarantee)
This page is left blank intentionally (last page)
Page 10 of 10
European Society for Clinical Virology
(Company limited by guarantee)
London - United Kingdom
Financial Statements
as at
31 October 2024
EUROPEAN SOCIETY FOR CLINICAL VIROLOGY, LONDON Balance sheet accounts as at October 31, 2024
| 2024 | 2024 | 2023 | 2023 | |||
|---|---|---|---|---|---|---|
| Notes | EUR | GBP | EUR | GBP | ||
| 0.83430 | 0.87237 | |||||
| ASSETS | ||||||
| Bank account | 4 | 26’529 | 22’133 | 197’958 | 172’692 | |
| Debtor ECCI | 6’392 | 5’333 | - | - | ||
| 32’921 | 27’466 | 197’958 | 172’692 | |||
| LIABILITIES | ||||||
| Accounts payable | 163 | 136 | 23’922 | 20’869 | ||
| # | # | 163 | 136 | 23’922 | 20’869 | |
| GENERAL RESERVES | ||||||
| General reserves brought forward | 174’036 | 151’823 | 318’476 | 273’220 | ||
| Result of the year | -141’278 | -117’868 | -144’440 | -126’005 | ||
| Foreign exchange conversion | - | -6’625 | - | 4’608 | ||
| 32’758 | 27’330 | 174’036 | 151’823 | |||
| 32’921 | 27’466 | 197’958 | 172’692 |
~~ne 22/06/2025GEORGIOS SOURVINOS19:28~~ Authorized signature
Date ~~—_~~
The notes to the accounts form part of these financial statements Page 2
EUROPEAN SOCIETY FOR CLINICAL VIROLOGY, LONDON Income & Expenses accounts from 1 November 2023 to 31 October 2024
| 2024 | 2024 | 2023 | 2023 | ||
|---|---|---|---|---|---|
| Notes | EUR | GBP | EUR | GBP | |
| 0.83430 | 0.85790 | ||||
| INCOMES | |||||
| Membership fees | 24’490 | 20’432 | 30’583 | 26’679 | |
| Sponsorship | 10’500 | 8’760 | 5’618 | 4’901 | |
| Congress income | 5 | 37’669 | 31’427 | 47’718 | 41’628 |
| 72’659 | 60’619 | 83’919 | 73’208 | ||
| EXPENSES | |||||
| Travel grants | 51’546 | 43’005 | 84’578 | 73’783 | |
| Awards | 10’500 | 8’760 | - | - | |
| Workshop expenses | 89’340 | 74’536 | 91’469 | 79’795 | |
| Congress expenses | - | - | 23’378 | 20’394 | |
| Project expenses | 24’342 | 20’309 | |||
| Journal expenses | 1’755 | 1’464 | 4’690 | 4’091 | |
| Administrative expenses | 27’640 | 23’060 | 17’640 | 15’389 | |
| Bank charges | 3’814 | 3’182 | 6’604 | 5’761 | |
| Extraordinary expenses | 6 | 5’000 | 4’171 | - | - |
| 213’937 | 178’487 | 228’359 | 199’213 | ||
| Net loss of the year | -141’278 | -117’868 | -144’440 | -126’005 |
The notes to the accounts form part of these financial statements Page 3
EUROPEAN SOCIETY FOR CLINICAL VIROLOGY, LONDON Notes to the Accounts of October 31, 2024
1- GENERAL
EUROPEAN SOCIETY FOR CLINICAL VIROLOGY "ESCV”, is registered as Charity under reference number 1099537.
The Private Limited Company by guarantee reference number is 04620455.
ESCV was incorporated on December 18, 2002.
The mission of ESCV is to provide a forum for virologists, scientists and physicians interested in all aspects of Clinical Virology and human viral diseases.
The registered office is at Charles Darwin House, 12 Roger Street, London WC1N 2JU, United Kingdom.
ESCV officers are :
-
Pamela Josephine Vallely
-
Catherine Moore
-
Xavier Lopez Labrador
-
Georgios Sourvinos
-
Mariet Feltkamp
-
Heli Harvala
-
Maria Sao Jose Garcia Alexandre Naschimento
-
- Annelies Riezebos-Brilman
2 - AUDIT EXEMPTION
For the year ending 31 October 2024, the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476 of the Companies Act 2006
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies’ regime.
3 – EMPLOYEES
No employees for this year.
4 – BANK ACCOUNT
Represent unrestricted cash balance in Euro held at BBVA Bank in Spain.
5 – CONGRESS INCOME
Income received for the ESCV meeting organised in 2023 in Milan.
6 – EXTRAORDINARY EXPENSES
The payment received on August 8th, 2022, was considered as sponsorhip. This has been reclassed in deduction of the advance done to ECCI.
Page 4
Independent examiner's report on the accounts
Section A Independent Examiner’s Report
Report to the trustees/ Charity Name members of European Society for Clinical Virology On accounts for the year 31[st] October 2024 Charity no 1099537 ended (if any) Set out on pages 2 (remember to include the page numbers of additional sheets)
I report to the trustees on my examination of the accounts of the above charity (“the Trust”) for the year ended 31/10 / 2024 .
- Responsibilities and As the charity trustees of the Trust, you are responsible for the preparation basis of report of the accounts in accordance with the requirements of the Charities Act 2011 (“the Act”).
I report in respect of my examination of the Trust’s accounts carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.
Independent I have completed my examination. I confirm that no material matters have examiner's statement come to my attention (other than that disclosed below *) in connection with the examination which gives me cause to believe that in, any material respect:
-
accounting records were not kept in accordance with section 130 of the Act or
-
the accounts do not accord with the accounting records
I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in order to enable a proper understanding of the accounts to be reached.
- Please delete the words in the brackets if they do not apply.
----- Start of picture text -----
Date: May 9 [th] 2025
----- End of picture text -----
Signed: Name: Susanne Dudman ~~Pe~~ Relevant professional Senior Medical Officer and Professor qualification(s) or body Member ESCV (if any): Address: Oslo University Hospital, University of Oslo P.O.Box 4950 Nydalen 0424 Oslo, Norway
October 2018
1
IER
Section B Disclosure
Only complete if the examiner needs to highlight matters of concern (see CC32, Independent examination of charity accounts: directions and guidance for examiners).
Give here brief details of any items that the examiner wishes to disclose .
None.
October 2018
2
IER